Investors seeking to outperform the market often focus on hand-picking stocks. Selecting the right ones has proven to be a key factor in boosting wealth.
AC Immune SA (NASDAQ: ACIU) closed the day trading at $3.38 down -11.98% from the previous closing price of $3.84. In other words, the price has decreased by -$11.98 from its previous closing price. On the day, 0.55 million shares were traded. ACIU stock price reached its highest trading level at $3.88 during the session, while it also had its lowest trading level at $3.38.
Ratios:
For a better understanding of ACIU, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.33 and its Current Ratio is at 1.33. In the meantime, Its Debt-to-Equity ratio is 0.07 whereas as Long-Term Debt/Eq ratio is at 0.05.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of. The stock’s future direction. In the most recent recommendation for this company, BTIG Research on May 31, 2024, initiated with a Buy rating and assigned the stock a target price of $8.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Oct 03 ’25 when ANDREA M.A PFEIFER bought 45,000 shares for $3.13 per share.
ANDREA M.A PFEIFER bought 35,000 shares of ACIU for $83,300 on Sep 12 ’25. On Jul 24 ’25, another insider, ANDREA M.A PFEIFER, who serves as the Officer of the company, bought 20,000 shares for $2.34 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ACIU now has a Market Capitalization of 340028000 and an Enterprise Value of 217918032. For the stock, the TTM Price-to-Sale (P/S) ratio is 10.02 while its Price-to-Book (P/B) ratio in mrq is 3.17. Its current Enterprise Value per Revenue stands at 7.536 whereas that against EBITDA is -4.478.
Stock Price History:
The Beta on a monthly basis for ACIU is 1.61, which has changed by 0.12666667 over the last 52 weeks, in comparison to a change of 0.19088471 over the same period for the S&P500. Over the past 52 weeks, ACIU has reached a high of $4.00, while it has fallen to a 52-week low of $1.43. The 50-Day Moving Average of the stock is 21.49%, while the 200-Day Moving Average is calculated to be 49.18%.
Shares Statistics:
Over the past 3-months, ACIU traded about 240.22K shares per day on average, while over the past 10 days, ACIU traded about 473950 shares per day. A total of 88.04M shares are outstanding, with a floating share count of 61.06M. Insiders hold about 38.28% of the company’s shares, while institutions hold 25.11% stake in the company. Shares short for ACIU as of 1760486400 were 1576999 with a Short Ratio of 6.56, compared to 1757894400 on 1577354. Therefore, it implies a Short% of Shares Outstanding of 1576999 and a Short% of Float of 3.3099998.
Earnings Estimates
AC Immune SA (ACIU) is presently subject to a detailed evaluation by 2.0 analysts, each offering their unique perspectives on its market standing.The consensus estimate for the next quarter is -$0.17, with high estimates of -$0.17 and low estimates of -$0.18.
Analysts are recommending an EPS of between -$0.7 and -$0.75 for the fiscal current year, implying an average EPS of -$0.73. EPS for the following year is -$0.6, with 2.0 analysts recommending between -$0.55 and -$0.64.
Revenue Estimates
A total of 3 analysts have provided revenue estimates for ACIU’s current fiscal year. The highest revenue estimate was $6M, while the lowest revenue estimate was $2.3M, resulting in an average revenue estimate of $3.99M. In the same quarter a year ago, actual revenue was $27.31MBased on 3 analysts’ estimates, the company’s revenue will be $36.46M in the next fiscal year. The high estimate is $90M and the low estimate is $6M.
